全文获取类型
收费全文 | 1506篇 |
免费 | 115篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 100篇 |
妇产科学 | 20篇 |
基础医学 | 131篇 |
口腔科学 | 27篇 |
临床医学 | 199篇 |
内科学 | 359篇 |
皮肤病学 | 45篇 |
神经病学 | 36篇 |
特种医学 | 310篇 |
外科学 | 156篇 |
综合类 | 18篇 |
预防医学 | 62篇 |
眼科学 | 6篇 |
药学 | 74篇 |
肿瘤学 | 87篇 |
出版年
2023年 | 6篇 |
2021年 | 16篇 |
2020年 | 12篇 |
2019年 | 11篇 |
2018年 | 26篇 |
2017年 | 13篇 |
2016年 | 16篇 |
2015年 | 22篇 |
2014年 | 28篇 |
2013年 | 38篇 |
2012年 | 45篇 |
2011年 | 24篇 |
2010年 | 37篇 |
2009年 | 32篇 |
2008年 | 21篇 |
2007年 | 47篇 |
2006年 | 31篇 |
2005年 | 40篇 |
2004年 | 41篇 |
2003年 | 23篇 |
2002年 | 22篇 |
2001年 | 36篇 |
2000年 | 25篇 |
1999年 | 39篇 |
1998年 | 101篇 |
1997年 | 77篇 |
1996年 | 84篇 |
1995年 | 58篇 |
1994年 | 57篇 |
1993年 | 67篇 |
1992年 | 24篇 |
1991年 | 20篇 |
1990年 | 31篇 |
1989年 | 45篇 |
1988年 | 32篇 |
1987年 | 44篇 |
1986年 | 32篇 |
1985年 | 37篇 |
1984年 | 29篇 |
1983年 | 22篇 |
1982年 | 25篇 |
1981年 | 25篇 |
1980年 | 29篇 |
1979年 | 11篇 |
1978年 | 22篇 |
1977年 | 20篇 |
1976年 | 23篇 |
1975年 | 20篇 |
1974年 | 6篇 |
1971年 | 6篇 |
排序方式: 共有1632条查询结果,搜索用时 0 毫秒
1.
Ketai LH; Williamson MR; Telepak RJ; Levy H; Koster FT; Nolte KB; Allen SE 《Radiology》1994,191(3):665
2.
3.
荧光原位杂交技术分析人结肠菌群方法研究 总被引:2,自引:0,他引:2
建立荧光原位杂交技术分析人体内结肠菌群的方法。取受试者新鲜粪便 ,选用 5种特异性的 16SrRNA寡核苷酸探针 ,检测粪便样本收集后的保存时间、温度 ,离心条件及样本固定液存放时间对杂交计数结果的影响。结果建立最佳实验条件为 :粪便样本收集后应尽快在 4℃下保存 ,放置时间不要超过 12小时即作处理 ;样本的适宜离心条件为 70 0g 2分钟 ;样本用多聚甲醛固定后在 - 80℃下存放时间不要超过 5个月。该方法具有较好的稳定性 ,可以有效地检出个体之间结肠菌群的差异。 相似文献
4.
5.
Trophic effects of unsulfated cholecystokinin on mouse pancreas and human pancreatic cancer. 总被引:2,自引:0,他引:2
The effect of unsulfated cholecystokinin on pancreatic growth was evaluated in two experimental models in vivo and in vitro. Mice were injected with sulfated cholecystokinin (CCKs) or unsulfated cholecystokinin (CCKu) (10 or 20 micrograms/kg) or vehicle twice daily for 15 days. Animals were then killed and pancreatic weights, protein, amylase, and DNA content were evaluated. In vitro, growth was evaluated by DNA synthesis and viable cell counts. MIA PaCa-2 and BxPC-3 human pancreatic cancer cells were treated with CCKs or CCKu (10(-12) to 10(-9) M) for 48 or 72 h in the presence of [3H]thymidine to evaluate DNA synthesis. Viable cell counts were performed on both cell lines grown in the presence or absence of unsulfated CCK (10(-12) to 10(-9) M) for 96 h. Pancreatic weight, protein, amylase, and DNA were significantly increased in animals treated with either CCKs or CCKu. However, pancreatic weight, protein, and amylase were significantly higher in mice treated with CCKs compared to CCKu (p less than 0.005). DNA content and index of hyperplasia were the same whether mice were treated with CCKs or CCKu. CCKu was as potent a stimulus for DNA synthesis as CCKs in MIA PaCa-2 and BxPC-3 cells. Finally, CCKu increased cell counts in both pancreatic cancer cell lines. These data suggest that the mechanisms responsible for CCK-induced growth of normal pancreas and pancreatic cancer may differ from those that regulate secretion. 相似文献
6.
7.
8.
9.
In this open-label, randomized, cross-over study, 12 healthy subjects received four doses of a new sustained-release formulation of diltiazem hydrochloride for six consecutive days. Blood samples were drawn on days 5 and 6 for determination of plasma diltiazem and desacetyldiltiazem levels. The peak concentrations after 120, 240, 360, and 480 mg of diltiazem were 48.1, 112.6, 180.9, and 276.8 ng/ml, respectively, while the mean minimum concentrations were 6.3, 14.6, 24.9, and 44.6 ng/ml. The areas under the concentration-time curves were 702, 1,642, 2,622, and 4,004 ng.hr/ml. Prolonged, continuous absorption of diltiazem was noted over the 24-hour dosing period. The dose-adjusted mean steady-state plasma diltiazem levels after the four doses were significantly different, consistent with diltiazem's nonlinear absorption, but the plasma profiles were similar, indicating that the diltiazem release rate was not dose-dependent. Therapeutic plasma diltiazem levels (greater than or equal to 40 ng/ml) were maintained for 24 hours after the three larger doses. The changes in the pharmacokinetics of desacetyldiltiazem over the four diltiazem doses were similar to those of diltiazem. The number of adverse treatment experiences tended to increase with the higher doses, but none were severe. The results indicate that, according to their pharmacokinetic profiles, doses of 240 mg to 480 mg of diltiazem are suitable for once-daily administration. 相似文献
10.